Chugai licenses SGLT2 inhibitor CSG452 in Japan to Kowa and Sanofi

Japanese drugmaker Chugai Pharmaceutical (TYO: 4519), which is majority owned by Swiss major Roche (ROG: SIX), has entered into license agreements for its original compound SGLT2 inhibitor CSG452, for which Chugai is currently conducting clinical development for type 2 diabetes, with Japan’s privately-owned Kowa and France’s Sanofi (Euronext: SAN), in Japan.

Under the agreement, the three companies, Chugai, Kowa and Sanofi will co-develop the compound, and Kowa and Sanofi will file the application for marketing authorization under their own brand names, while Chugai will manufacture the products for supply to the two companies. Under the terms of the agreements, Chugai will receive milestone payments from Kowa and Sanofi.

Parent Roche returned overseas rights